Analyst Reco. Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 11/02/2026 GMT			5-day change	1st Jan Change
25.99 ^USD	-3.56%		-3.56%	-6.24%

02-05	Beam Therapeutics Inc. Announces Resignation of Carole Ho from the Board of Directors, Effective February 27, 2026	CI
01-14	Beam Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 05:15 PM

Analyst Reco.

01-07	UBS Initiates Beam Therapeutics at Neutral With $28 Price Target	MT
01-06	BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating	MT
09/10/25	Jefferies Initiates Beam Therapeutics at Buy Rating, $41 Price Target	MT
03/04/25	RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk	MT
28/03/25	BofA Securities Upgrades Beam Therapeutics to Buy From Neutral	MT
10/03/25	Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target	MT
26/02/25	RBC Raises Price Target on Beam Therapeutics to $26 From $24, Keeps Sector Perform, Speculative Risk	MT
29/01/25	Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral	MT
06/11/24	Beam Therapeutics Gets Upgrade From Leerink Partners; Shares Rise	MT
06/11/24	RBC Capital Adjusts Price Target on Beam Therapeutics to $24 From $27, Maintains Sector Perform, Speculative Risk Rating	MT
06/11/24	Leerink Partners Upgrades Beam Therapeutics to Outperform From Market Perform, Adjusts PT to $39 From $27	MT
16/10/24	Scotiabank Initiates Beam Therapeutics at Sector Perform With $24 Price Target	MT
18/09/24	JonesTrading Initiates Beam Therapeutics at Hold	MT
23/07/24	Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy	MT
23/07/24	HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target	MT
09/07/24	RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	MT
04/04/24	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
28/02/24	Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	MT
28/02/24	RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	MT
27/02/24	Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	MT
29/01/24	JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	MT
15/12/23	BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	MT
08/12/23	Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	MT
17/10/23	Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating	MT
09/08/23	Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Analyst Reco.

Filters